PC
ABBV icon

Paulson & Co’s AbbVie ABBV Stock Holding History

Paulson & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-139,700
Closed -$8.28M – 98
2015
Q4 		$8.28M Buy
+139,700
New +$8.05M 0.05% 51
2014
Q4 		– Sell
-13,000,000
Closed -$751M – 64
2014
Q3 		$751M Buy
+13,000,000
New +$722M 3.12% 10

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Paulson & Co's ABBV Position: Q1 2016 in Review

Paulson & Co sold out of AbbVie (ABBV) in Q1 2016, closing a stake of 139,700 shares — an estimated $8.28M sold.

Paulson & Co first reported a position in ABBV in Q3 2014 and held it in 2 quarters. The position peaked at $751M in Q3 2014. 1,638 funds tracked by Wall St. Rank hold ABBV as of Q1 2016.

  • Paulson & Co reported no remaining AbbVie position as of Q1 2016 after selling out during the quarter.
  • Paulson & Co sold 139,700 AbbVie shares in Q1 2016, an estimated $8.28M.
  • Paulson & Co first reported a position in AbbVie in Q3 2014 and held it in 2 quarters.
  • Paulson & Co's AbbVie position peaked at $751M in Q3 2014.
  • 1,638 funds tracked by Wall St. Rank held AbbVie as of Q1 2016.

Based on Paulson & Co's 13F filing for Q1 2016, filed 16 May 2016.